Brequinar

Drug Profile

Brequinar

Alternative Names: Bipenquinate; Brequinar sodium; DUP 785; NSC 368390; NSC 369390

Latest Information Update: 17 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Biphenyl compounds
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Cytomegalovirus infections; Transplant rejection

Most Recent Events

  • 18 Dec 1998 A study has been added to the Transplant rejection pharmacodynamics section
  • 16 Dec 1998 Phase-II clinical trials for Transplant rejection in USA (PO)
  • 16 Dec 1998 A study in transplant patients has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top